



HAL
open science

Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010

J. G. Loeber, D. Platis, R. H. Zetterström, S. Almashanu, F. Boemer, J. R. Bonham, P. Borde, I. Brincat, D. Cheillan, E. Dekkers, et al.

► **To cite this version:**

J. G. Loeber, D. Platis, R. H. Zetterström, S. Almashanu, F. Boemer, et al.. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. International Journal of Neonatal Screening, 2021, 7 (1), pp.15. 10.3390/ijns7010015 . inserm-03337431

HAL Id: inserm-03337431

<https://inserm.hal.science/inserm-03337431>

Submitted on 8 Sep 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Article

Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010

J. Gerard Loeber ^{1,*}, Dimitris Platis ², Rolf H. Zetterström ³ , Shlomo Almashanu ⁴, François Boemer ⁵ , James R. Bonham ⁶, Patricia Borde ⁷, Ian Brincat ⁸, David Cheillan ⁹, Eugenie Dekkers ¹⁰, Dobry Dimitrov ¹¹, Ralph Fingerhut ¹², Leifur Franzson ¹³ , Urh Groselj ¹⁴ , David Hougaard ¹⁵, Maria Knapkova ¹⁶ , Mirjana Kocova ¹⁷ , Vjosa Kotori ¹⁸, Viktor Kozich ¹⁹ , Anastasiia Kremezna ²⁰, Riikka Kurkijärvi ²¹, Giancarlo La Marca ²², Ruth Mikelsaar ²³, Tatjana Milenkovic ²⁴, Vyacheslav Mitkin ²⁵, Florentina Moldovanu ²⁶, Uta Ceglarek ²⁷, Loretta O'Grady ²⁸, Mariusz Oltarzewski ²⁹, Rolf D. Pettersen ³⁰, Danijela Ramadza ³¹, Damilya Salimbayeva ³² , Mira Samardzic ³³ , Markhabo Shamsiddinova ³⁴ , Jurgita Songailienė ³⁵, Ildiko Szatmari ³⁶, Nazi Tabatadze ³⁷, Basak Tezel ³⁸, Alma Toromanovic ³⁹, Irina Tovmasyan ⁴⁰, Natalia Usurelu ⁴¹, Parsla Vevere ⁴², Laura Vilarinho ⁴³ , Marios Vogazianos ⁴⁴, Raquel Yahyaoui ⁴⁵ , Maximilian Zeyda ⁴⁶ and Peter C. J. I. Schielen ¹



Citation: Loeber, J.G.; Platis, D.; Zetterström, R.H.; Almashanu, S.; Boemer, F.; Bonham, J.R.; Borde, P.; Brincat, I.; Cheillan, D.; Dekkers, E.; et al. Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. *Int. J. Neonatal Screen.* **2021**, *7*, 15. <https://doi.org/10.3390/ijns7010015>

Academic Editor: Inken Brockow

Received: 20 January 2021

Accepted: 24 February 2021

Published: 5 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

- ¹ International Society for Neonatal Screening (ISNS) Office, 3721CK Bilthoven, The Netherlands; peter.schielen@gmail.com
- ² Department of Newborn Screening, Institute of Child Health, 11527 Athens, Greece; dplatis@ich.gr
- ³ Centre for Inherited Metabolic Diseases, Karolinska University Hospital and Department of Molecular Medicine and Surgery, Karolinska Institute, SE-17 76 Stockholm, Sweden; rolf.zetterstrom@sll.se
- ⁴ Newborn Screening Laboratories, Tel-HaShomer, 52621 Ramat Gan, Israel; shlomo.almashanu@sheba.health.gov.il
- ⁵ CHU-Domaine du Sart Tilman, 4000 Liège, Belgium; f.boemer@chuliege.be
- ⁶ Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK; j.bonham@nhs.net
- ⁷ Laboratoire National de Santé, 3555 Dudelange, Luxembourg; patricia.borde@lns.etat.lu
- ⁸ Mater Dei Hospital, Tal-Qroqq Msida, MSD2090 Msida, Malta; ian.brincat@gov.mt
- ⁹ Groupement Hospitalier Est, 69500 Bron, France; david.cheillan@chu-lyon.fr
- ¹⁰ Centre for Population Research, National Institute for Public Health and the Environment (RIVM), 3720BA Bilthoven, The Netherlands; eugenie.dekkers@rivm.nl
- ¹¹ National Genetic Laboratory, Hospital Maichin Dom, 1431 Sofia, Bulgaria; s3d@abv.bg
- ¹² Neonatal Screening Laboratory, Children's Hospital, CH-8032 Zürich, Switzerland; ralph.fingerhut@gmail.com
- ¹³ Department Genetics & Molecular Medicine, Landspítali, Reykjavík 108, Iceland; leifurfr@landspitali.is
- ¹⁴ University Children's Hospital, 1000 Ljubljana, Slovenia; urh.groselj@gmail.com
- ¹⁵ Staten Serum Institute, 2300 Copenhagen, Denmark; dh@ssi.dk
- ¹⁶ Newborn Screening Centre, Banská Bystrica 97401, Slovakia; maria.knapkova@dfnbb.sk
- ¹⁷ Medical Faculty, 1000 Skopje, North Macedonia; mirjanakocova@yahoo.com
- ¹⁸ University Clinical Centre, Pristina 10000, Kosovo; vjosakotori@hotmail.com
- ¹⁹ Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague 12808, Czech Republic; viktor.kozich@lf1.cuni.cz
- ²⁰ Clinical and Diagnostic Center "Pharmbiotest", LLC 93000 Rubizhne, Ukraine; kremezna@pharmbiotest.com.ua
- ²¹ Newborn Screening Centre, Turku University Hospital, 20521 Turku, Finland; Riikka.Kurkijarvi@tyks.fi
- ²² Meyer Hospital, 50139 Florence, Italy; g.lamarca@meyer.it
- ²³ Medical Faculty, University of Tartu, 50411 Tart, Estonia; ruth.mikelsaar@ut.ee
- ²⁴ Mother and Child Health Care Institute of Serbia, Belgrade 11070, Serbia; tanjamil5e@gmail.com
- ²⁵ Neonatal Screening Center, 115580 Moscow, Russia; mitkinsl@rambler.ru
- ²⁶ National Institute for Mother and Child Health, 050474 Bucharest, Romania; florentina.moldovanu@gmail.com
- ²⁷ University Clinic, 04103 Leipzig, Germany; Uta.Ceglarek@medizin.uni-leipzig.de
- ²⁸ Newborn Blood Spot Screening Laboratory, Dublin 1, Ireland; loretta.ogrady@cuh.ie
- ²⁹ Institute of Mother and Child, 01-211 Warsaw, Poland; oltarzewski@op.pl
- ³⁰ Norwegian National Unit for Newborn Screening, 0424 Oslo, Norway; rdpetter@ous-hf.no
- ³¹ University Hospital Medical Centre Zagreb, 10000 Zagreb, Croatia; dramadza@gmail.com
- ³² Republican Scientific Centre for Gynaecology and Perinatology, Almaty 050020, Kazakhstan; Sdamilya@mail.ru
- ³³ Institute for Sick Children, 81000 Podgorica, Montenegro; samardzic@t-com.me
- ³⁴ Republican Center Mother and Child Screening, Tashkent 100164, Uzbekistan; markhabo2@mail.ru

- ³⁵ Centre for Medical Genetics, 08661 Vilnius, Lithuania; jurgita.songailiene@santa.lt
³⁶ Children's Clinic, 1083 Budapest, Hungary; szatmari.ildiko@med.semmelweis-univ.hu
³⁷ NeugoGenetic and Metabolic Center, Tbilisi 0194, Georgia; n_tabatadze@hotmail.com
³⁸ Child and Adolescent Health Department, 06430 Ankara, Turkey; Basak.Tezel@saglik.gov.tr
³⁹ Department of Pediatrics, University Clinical Centre, Tuzla 75000, Bosnia and Herzegovina; almotoromanovic88@gmail.com
⁴⁰ Arbes Health Care Centre, Yerevan 0014, Armenia; irinatovmasyan@yahoo.com
⁴¹ National Centre Health and Reproductive & Medical Genetics, 2062 Chisinau, Moldova; natalia.usurelu@yahoo.com
⁴² Children's University Hospital, 1004 Riga, Latvia; parslavevere@inbox.lv
⁴³ National Institute of Health, 4000-055 Porto, Portugal; laura.vilarinho@insa.min-saude.pt
⁴⁴ Center for Preventive Paediatrics, 3022 Limassol, Cyprus; vogazianos@cpp.org.cy
⁴⁵ Málaga Regional University Hospital. Institute of Biomedical Research IBIMA, 29011 Málaga, Spain; raquelyahyaoui@gmail.com
⁴⁶ Department of Pediatrics and Adolescent Medicine, 1090 Vienna, Austria; maximilian.zeyda@meduniwien.ac.at
- * Correspondence: gerard.loeber@gmail.com; Tel.: +31-6-4616-3922

Abstract: Neonatal screening (NBS) was initiated in Europe during the 1960s with the screening for phenylketonuria. The panel of screened disorders ("conditions") then gradually expanded, with a boost in the late 1990s with the introduction of tandem mass spectrometry (MS/MS), making it possible to screen for 40–50 conditions using a single blood spot. The most recent additions to screening programmes (screening for cystic fibrosis, severe combined immunodeficiency and spinal muscular atrophy) were assisted by or realised through the introduction of molecular technologies. For this survey, we collected data from 51 European countries. We report the developments between 2010 and 2020 and highlight the achievements reached with the progress made in this period. We also identify areas where further progress can be made, mainly by exchanging knowledge and learning from experiences in neighbouring countries. Between 2010 and 2020, most NBS programmes in geographical Europe matured considerably, both in terms of methodology (modernised) and with regard to the panel of conditions screened (expanded). These developments indicate that more collaboration in Europe through European organisations is gaining momentum. We can only accomplish the timely detection of newborn infants potentially suffering from one of the many rare diseases and take appropriate action by working together.

Keywords: neonatal screening; newborn screening; congenital metabolic disorders; rare diseases; dried blood spot screening; congenital endocrine disorders; International Society for Neonatal Screening; ISNS; public health

1. Introduction

Neonatal screening, called newborn screening (NBS) in some countries, was initiated in Europe during the 1960s, when small programmes to screen for phenylketonuria (PKU) started in, e.g., the UK [1]. The detection of the biomarker for the disease, phenylpyruvic acid in urine, was a first and necessary step for screening as early as the 1930s [2–4]. However, the major breakthrough was the development of a simple and cheap screening method for PKU using dried blood spots (DBS) on a special collection device of a blood sample taken from the heel of newborn infants by Guthrie [5]. A few years later, Dusault introduced the radio-immunochemical methods for measuring the concentrations of thyroid hormones in DBS to detect congenital hypothyroidism (CH), enabling a second disease to be detected in NBS [6]. Gradually, the panel of screened disorders ("conditions") expanded, with a boost in the late 1990s and the first decade of the 21st century with the introduction of tandem mass spectrometry (MS/MS) in NBS, making it possible to screen for 40–50 conditions using a single blood spot [7–9]. The most recent additions to screening programmes (screening for cystic fibrosis (CF), severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA)) were assisted by or realised through the introduction

of molecular technologies. The Wilson and Jungner criteria [10] were the primary road map toward designing a screening policy taking into consideration prevalence, diagnostics, treatability, etc. However, huge advances in molecular technologies and other analytical innovations have allowed policymakers to include an ever-expanding list of disorders in their national programmes, sometimes stretching the intent of the criteria.

In the context of this paper, Europe is a geographical area consisting of around 50 countries situated east of the Atlantic Ocean, north of or in the Mediterranean Sea and west of the Ural Mountains, including all of Russia. In addition, the International Society for Neonatal Screening (ISNS) has decided to regard five former USSR republics, positioned east of the Ural (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan), to be part of Europe in view of their historically close ties to Russia [11]. Similarly, the ISNS has recognised Israel to be part of Europe following their request. In 2019, the total population of these countries was around 915 million, with an average annual birth rate of around 11.9 per 1000 people, leading to some 10.9 million newborn infants [12,13].

In Europe, NBS was introduced in the western part of the continent during the 1960s, spreading to the eastern part in the course of the next four decades (Figure 1). In virtually all countries, there is now some kind of institutionalised neonatal screening. Some countries are so small that screening is performed in a larger neighbouring country (Liechtenstein covered by Switzerland, Andorra and Monaco by France, San Marino by Italy, Kosovo partly by Serbia). In Albania, most of Kosovo and Tajikistan, there is no official NBS programme yet, but in Albania, there are local initiatives in some hospitals.

NBS starting year




Figure 1. Map of the International Society for Neonatal (ISNS) European region, colour coded by the starting year of neonatal screening. Arrow indicates Malta (green). Albania and Tajikistan (in blue-hatched white) have no neonatal screening programme. Grey areas fall outside the geographical region under consideration. White areas are bodies of water.

Although the value of NBS has been widely recognised, its introduction, depending on health care structure, available funds, local politics, input from professional groups and the general public, has led to quite varying approaches in the way these programmes have been set up, financed and governed. To obtain more information on these differences, an online survey, commissioned by the European Union to a European project team, was compiled in 2010 in which all aspects of screening programmes were addressed [14]. The survey covered the EU member states, (potential) candidate member states and European Free Trade Association (EFTA countries), totalling 38 countries. Results showed large

variations in the panel of screened conditions (ranging from none to over 30 conditions), in specimen collection time after birth, screening methodology and storage time of residual specimen material (varying from a few months to 'indefinite'). In addition, there were considerable differences in the process of confirmatory diagnostics, treatment and follow-up of screening results. In 2011, the project group, based on this inventory, provided a list of 60 recommendations to the EU Commission [15], but so far, none of them have been taken up by the EU. On the other hand, the EU has stimulated the formation of European Reference Networks (ERNs), i.e., collaborations of institutes in member states with aligned research and diagnostic aims, particularly in the area of Rare Diseases, with the aim of providing greater equity of access to centres of excellence for patients in Europe. The ERNs are focused on both diagnosis and treatment. The inclusion of neonatal screening seems evident, but the attention of the ERNs for neonatal screening could still be improved [16].

The initial initiative in 2010 to make an inventory of the state of neonatal screening in Europe has led to an informal network of colleagues, comprising nearly all members of the ISNS, who have been asked to update their data biennially, most recently in 2020.

In this paper, we report the developments between 2010 and 2020 and highlight the progress made in this period. We also identify areas where considerable progress can still be made, mainly by exchanging knowledge and learning from experiences in neighbouring countries. Smaller parts of the results have been published elsewhere [17–21].

2. Materials and Methods

2.1. Scope of the Survey

For most of the countries, data were collected from local members of the ISNS who are directly involved in their national NBS programme and regarded as being knowledgeable on all major aspects. When a country lacked the presence of an ISNS member, we tried to establish contacts through personal relations between ISNS members and local screening laboratories, e.g., in the former USSR republics.

2.2. Data Collection

Data were gathered using a standard form during the period 2012–2018. A slightly different questionnaire was used to obtain additional data in 2020, which was disseminated to the same countries in light of the preparation of yearly regional reports assembled for the ISNS. Questions pertained to all aspects of screening, with special reference to the analytical phase. The elements of the questionnaires are listed in Supplementary Files S1 and S2.

In several countries, neonatal screening programmes also include screening for congenital critical heart disease and for hearing disabilities. This paper is limited to conditions identified by screening using neonatal blood samples.

3. Results and Discussion

Data were received for 51 countries. Table 1 is an overview of some general characteristics concerning the population screened, as well as some logistical information concerning the NBS programmes. Tables 2 and 3 highlight the conditions that are part of the screening panel.

Table 1. Country data.

Country	Approx. Population 2020 (Million) ¹	Approx. Number of Infants	Number Screening Laboratories	Average Number Samples Per Lab. ²	Interval Birth-Sampling (hrs)	Interval Sampling-Analysis (Days)	% Infants Screened	Information to Parents Available?	Consent Participation?	Consent Storage?	Length Storage (yrs)	Normal Results Reported to Parents?
Albania (no screening)	3.0	36,000	n.a. ³	n.a.	n.a.	n.a.	n.a.	n.a.	n.a	n.a	n.a	n.a.
Austria	8.8	87,000	1	87,000	36–72	1–3	>99.5	yes	no	no	10	no
Armenia	3.1	36,000	2 ⁴	36,000	48–96	1–5	99.8	yes	yes	no	1 indef.	no
Azerbaijan	9.7	170,000	1	35,000	48–72	3–5	30	yes	no	no	n.d.	n.d.
Belarus	9.8	108,000	1	108,000	72–120	1–5	n.d.	yes	no	no	5	n.d.
Belgium	10.5	117,000	4	30,000	48–120	2	99.8	yes	no	no	5	no
Bosnia-Herzegovina	3.3	28,000	3 ⁴	9000	48–96	1–7	96	no	no	no	10	no
Bulgaria	7.4	61,000	2 ⁴	61,000	72–120	5–10	n.d.	no	yes/no	no	20	n.d.
Croatia	4.2	36,200	1	36,200	48–72	3–5	100	yes	no	no	5	no
Cyprus ⁵	1.1	9500	1	9500	48–168	5–10	>99.9	yes	yes	no	2	no
Czech Republic	10.6	113,000	4 ⁴	56,000	48–72	2.5	100	yes	yes	no	5	no
Denmark	5.6	63,000	1	63,000	48–72	1–2	99.1	yes	yes	yes	indef.	online
Estonia	1.3	13,500	1	13,500	48–72	2–5	99.55	yes	yes	no	>25	no
Finland	5.5	45,000	1 ⁴	45,000	48–120	1–5	99	yes	yes	no	varies	online
France	67	760,000	16	47,000	48–72	2–3	99.96	yes	yes ⁶	no	1	no
Georgia	3.7	48,500	1	48,500	48–72	14–15	100	yes	no	no	15	no
Germany	80	787,000	11	71,000	36–72	2–3	100	yes	yes	yes	<1	no
Greece	10.5	80,000	1	89,000	48–72	6–8	100	yes	no	no	2	no
Hungary	10	90,000	2	50,000	48–72	3–4 *	99.99	yes	no	no	indef.	no
Iceland	0.35	4500	1	4500	48–72	3–5	100	yes	yes	yes	indef.	online
Ireland	4.9	59,700	1	59,700	72–120	1–2	>99.5	yes	yes	yes	10	no
Israel	9.2	194,000	1	194,000	36–72	1–3	99.8	yes	no	no	5	online
Italy	60.5	434,000	15	28,900	48–72	1–4	96.7	yes	no	no	2–10	no
Kazakhstan	18.7	402,000	21	20,000	24–72	1–2	96.5	yes	yes	no	3	no
Kosovo	1.8	25,000	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a	n.a	n.a	n.a.
Kyrgyzstan	7.0	160,000	1	32,000	48–72	3–5	30	yes	no	no	n.d.	n.d.
Latvia	1.9	20,800	1	20,000	48–72	5–7	98.5	yes	yes	no	7	online

Table 1. Cont.

Country	Approx. Population 2020 (Million) ¹	Approx. Number of Infants	Number Screening Laboratories	Average Number Samples Per Lab. ²	Interval Birth-Sampling (hrs)	Interval Sampling-Analysis (Days)	% Infants Screened	Information to Parents Available?	Consent Participation?	Consent Storage?	Length Storage (yrs)	Normal Results Reported to Parents?
Lithuania	2.8	24,600	1	24,600	48–96	2–9	99.6	yes	yes	no	20	no
Luxembourg	0.6	7200	1	7200	48–72	4	>99	yes	yes	no	indef.	no
Malta	0.48	4400	2 ⁴	4400	72–120	5	99.7	yes	yes	no	indef.	no
Moldova	3.5	37,400	1	37,400	>48	30	92.3	yes	yes	no	0	n.d.
Montenegro	0.62	7200	1	7200	24–72	1–3	100	no	no	no	0.5	no
Netherlands	17.8	168,500	5	34,000	72–96	1–3	99.3	yes	yes	yes	5	mail
North Macedonia	2.1	20,000	1	20,000	32–72	3	>98	yes	no	yes	3	no
Norway	5.3	55,500	1	55,500	48–72	1–3	>99	yes	yes	yes	indef.	no
Poland	38.4	373,000	6	62,000	48–96	3	99.8	yes	yes	yes	5	online
Portugal	10.3	87,300	1	87,300	48–72	1–3	99.5	yes	yes	no	5	online
Romania ⁷	19.6	185,600	5	31,500	48–72	18	85	yes	yes	no	5	no
Russia	142	1,670,000	78 ⁴	20,000	48–72	3–5	90–92	yes	yes	no	3	n.d.
Serbia	7.0	65,000	2	32,500	48–72	3–5	99	yes	no	no	5	no
Slovakia	5.4	57,000	1	57,000	72–96	2–3	100	yes	yes	no	indef.	no
Slovenia	2.07	20,000	1	20,000	48–72	1–2	>99	yes	no	no	indef.	no
Spain	46.5	372,000	15	24,800	24–72	3–10	99.2	yes	yes	yes	5-indef	mail
Sweden	10	116,000	1	116,000	48–72	1–3	>99.5	yes	yes	yes	indef.	no
Switzerland	8.1	88,000	1	88,000	72–96	2	>99.9	yes	yes	yes	indef.	no
Tajikistan (no screening)	9.4	291,000	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Turkey	84.3	1,300,000	2	650,000	48–72 *	1–2	97	yes	yes	yes	5	no
Turkmenistan	6.0	110,200	1	35,000	48–72	3–5	30	yes	no	no	n.d.	n.d.
United Kingdom	66.6	760,000	16	47,500	120	3–4	96.5	yes	yes	no	>5	mail
Ukraine	43.7	393,000	7	56,100	48–72	3	n.d.	yes	yes	n.a.	<0.5	mail
Uzbekistan	31.3	760,600	14	54,000	72–96	10.	95	yes	yes	n.d.	1	n.d.

Colour indications countries: EU member (brown), candidate EU member (fuchsia), potential candidate EU member (green), EFTA member (blue), Europe-other (purple). ¹ <https://worldpopulationreview.com/> (visited 14 November 2020); ² in larger countries, numbers vary largely; ³ n.d. = no data; n.a. = not applicable; ⁴ not all laboratories carry out the whole screening panel; ⁵ data regarding northern part of the Cyprus island not included; ⁶ France only consented to cystic fibrosis transmembrane conductance regulator (CFTR) analysis; ⁷ Romania total newborns includes Romanian infants born elsewhere; % screened excludes private labs.

Table 2. Cont.

	Endocrine Disorders			Amino Acidemias									Organic Acidemias									
	CH ¹	CAH	CF	PKU	MSUD	HCY	Tyr-1	Tyr-2	ASA	Cit.1/2	ARG	MAT I/III	GA1	IVA	3MCC	PA	MMA ³	BKT	HCS D	3HMG	MCD	
Montenegro	x		x																			
Netherlands	x	x	x	x	x		x						x	x	x	x	x			x	x	
N. Macedonia	x		p	x	x	x	x		x	x	x		x	x	x	x	x	x	x			x
Norway	x	x	x	x	x	x	x						x	x		x	x	x	x	x	x	x
Poland	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x	x	x		x		
Portugal	x		x	x	x	x	x	x	x	x	x		x	x	x	x	x			x		
Romania	x			x			x	x														
Russia	x	x	x	x								x										
Serbia	x		x	x												x						
Slovakia	x	x	x	x	x		x	x		x	x	x	x	x	x	x	x	x		x		
Slovenia	x			x	x		x						x	x	x	x	x	x	x	x	x	
Spain	x	p	x	x	p	p	p	p	p	p	p		x	p	p	p	p	p	p	p	p	p
Sweden	x	x		x	x	x	x		x	x	x		x	x		x	x	x				
Switzerland	x	x	x	x	x								x									
Tajikistan																						
Turkey	x	x	x	x																		
Turkmenistan	x	x	x	x																		
United Kingdom	x		x	x	x	x							x	x								
Ukraine	x	x	x	x	p	p	p	p	p	p	p		p	p	p		p	p	p			
Uzbekistan	x		p	x	p	p	p		p	p	p		p	p	p	p	p					
Total⁴	47	24 + 2	25 + 4	46	22 + 3	16 + 3	19 + 3	10 + 2	11 + 3	13 + 3	12 + 3	3	24 + 2	21 + 3	9 + 32	18 + 2	17 + 3	10 + 2	6 + 2	10 + 1	8 + 1	

Colour indications countries: EU member (brown), candidate EU member (fuchsia), potential candidate EU member (green), EFTA member (blue), Europe-other (purple).¹ for explanation of abbreviations, see the list in the main text; ² x = in screening panel; p = pilot/regional screening; ³ total number of conditions in screening panel; total number of pilots; ⁴ MMA includes MMAMut, Cbl deficiencies and Vitamin B12-deficiency; Note North Macedonia 30% full tandem mass spectrometry (MS/MS) spectrum; Russia 20% full MS/MS spectrum.

Table 3. Cont.

	Fatty acid Oxidation Disorders									Miscellaneous							Hemo	Total ³	
	GA2 ¹	MCAD	LCHAD/TFP	VLCAD	SCAD	CPT1	CPT2	CACT	CUD	RMD	GAL	BIOT	UDP	G6PD	xALD	SCID	SMA		SCD
Latvia											x	x							6
Lithuania											x								4
Luxembourg		x																	5
Malta																		x	3
Moldova																			1
Montenegro																			2
Netherlands		x	x	x		x					x	x			x	p		p	20 + 2
North Macedonia	x	x	x	x	x	x	x	x	x										25 + 1
Norway		x	x			x	x	x	x			x				x			23
Poland	x	x	x	x		x	x	x	x		p	x				p			27 + 2
Portugal	x	x	x	x		x	x	x	x										24
Romania																			4
Russia											x								6
Serbia																			3
Slovakia		x	x	x	x	x	x	x	x							p	p		25 + 2
Slovenia		x	x	x		x	x	x	x						p				19 + 1
Spain	p	x	x	p	p	p	p		p	p	p	p				p		x	7 + 26
Sweden	x	x	x	x		x	x	x	x		x	x				x			25
Switzerland		x									x	x				x			10
Tajikistan																			n.d.
Turkey												x							5
Turkmenistan											x			x					6
United Kingdom		x																x	9
Ukraine	p	p	p	p		p	p	p	p		p	p							4 + 24
Uzbekistan		p	p	p		p	p		p			p							2 + 19
Total³	11 + 2	26 + 2	20 + 2	19 + 3	+	17 + 3	16 + 3	15 + 1	15 + 3	+	17 + 3	13 + 3	1	3 + 2	1 + 3	7 + 6	0 + 5	4 + 3	

Colour indications countries: EU member (brown), candidate EU member (fuchsia), potential candidate EU member (green), EFTA member (blue), Europe-other (purple).¹ for explanation of abbreviations, see the list in the main text; ² x = in screening panel; p = pilot/regional screening; ³ total number of conditions in screening panel; total number of pilots; ⁴ no data; Note North Macedonia 30% full MS/MS spectrum; Russia 20% full MS/MS spectrum.

3.1. NBS Infrastructure

To determine the state of the NBS system, basic information on the infrastructure is necessary. This information includes data on birth, preanalytic data (mode of sampling, sample transport, laboratory organisation, analytical procedures, reporting of results and clinical partners) and diagnostic and clinical follow-up of results. It is important to realise that countries have their own distinguished manner of organising their health care system and that this also applies to the neonatal screening system.

In Table 1, the results are presented per country. In some countries, however, the NBS programme is carried out under the responsibility of autonomous parts of the country, such as in Belgium, Bosnia-Herzegovina, Germany, Italy, Spain and the United Kingdom. For a few countries, no data or limited data were available.

3.1.1. Number of Screening Laboratories and Average Annual Workload

Most countries have only one or two screening laboratories. Countries with a larger population generally have more laboratories, with Russia having 78 laboratories. There is no obvious relationship between the number of laboratories and the number of births, leading to varying annual workloads per laboratory. Due to changes in the structure of the neonatal screening programmes in recent years, the number of laboratories in France and Italy has decreased substantially. Finland introduced DBS screening in 2015 and has considered abandoning screening using cord blood. Also, Malta recently decided to switch from cord blood screening to DBS screening.

It is not easy to provide an optimal average number of samples per laboratory [14]. Of course, the input of labour and the use of the laboratory equipment should be as efficient as possible, which argues in favour of a high daily workload and, consequently, a low number of laboratories. A high daily workload would produce a more precise estimate of daily mean or median concentration for each analyte, and trends in measurements would present themselves timelier. This favours accurate daily quality assurance. It also makes it easier for the laboratory to obtain useful screening information on rare disorders. On the other hand, it can be argued that the screening process should be able to go on continuously with as few interruptions, e.g., by maintenance and technical failures, as possible. That would mean that all essential equipment would have to be available at least in duplicate. Therefore, it could be argued to include a higher number of closely collaborating laboratories, each with their own infrastructure, but with the possibility to provide backup for each other in case of emergencies or even calamities. The vast majority of countries are autonomous as far as newborn screening is concerned and do not want to rely on the resources of a neighbouring country. There is currently little cross-border collaboration for back-up laboratory facilities. However, Finland recently backed up Estonia when the latter had instrumentation problems.

In general, based on the data from Table 1, we can see that most countries with a total birth rate of around 100–20,000 neonates per year operate with a single screening laboratory, which is probably an efficient strategy. Under such conditions, it might be more economically sound, as well as scientifically beneficial, to use a single efficient operating unit to gather the entirety of data under a single managerial scheme. Above this birth rate, countries tend to have multiple screening laboratories. This may be related to the increased workload, but may also partly be influenced by various other factors, such as politico-geographical structure or other subdivisions of the country (e.g., Italy, Spain, France, Germany) and terrain and size (e.g., Russia). We also observed an opposite trend, where a higher-than-necessary number of labs are available (e.g., Serbia, Bosnia-Herzegovina), again possibly due to various socioeconomic or political factors. In general, an efficient design of the NBS network of a country will depend on a variety of factors that transcend scientific and efficiency considerations and consider the various other idiosyncrasies of each country.

3.1.2. Coverage

In the majority of the countries, the coverage, defined as the percentage of newborns included in neonatal screening, is higher than 90%. In many countries, coverage is even higher than 99% despite the fact that NBS is not mandated in most countries, with Italy being an exception. Reported coverages of, e.g., 99.9% or 100% need to be regarded with caution. Even with the best birth registries and neonatal screening registries, a number of eligible neonates will be missed in screening, and it should also be remembered that the figures quoted for coverage will include families who decline the offer of screening in countries where this is optional. In Kyrgyzstan and Turkmenistan, the screening programmes started only recently. The initial coverage of 30% needs attention and may rise in the future. In general, coverage seems to be unrelated to the need of an informed consent for NBS or the programme being mandated.

3.1.3. Screening Information, Parental Consent and Consent for Sample Storage

Most countries (94%) now have information materials for parents available either as written brochures or via websites. This is a significant improvement compared to 66% in 2010. Around 64% of the countries ask for consent, which is almost similar to the percentage in 2010. Consent for long-term storage of blood spot cards is requested in only 30% of countries (see Section 3.1.6.).

3.1.4. Sample Logistics

Almost all countries screen using blood taken from the heel of neonates. The recommended time for sampling after birth varies per country, with 13% of countries recommending sampling after 24 h, 67% after 48 h, 18% after 72 h and 2% even later. These differences are mostly due to differences in the organisation of the screening programme and maternity care. Some countries sample in the hospital before mother and child are discharged. In other countries, e.g., in the UK, the sample is taken by the midwife or health visitor when the mother and child have returned home. At any rate, the median sampling window of 48–72 h after birth is (much) later than, e.g., in the USA.

Differences in sampling time may also reflect differences in the screening panel. For some conditions, the optimal window to measure the corresponding screening parameter is earlier than others. Screening for primary CH in early samples may be affected by elevated thyrotropin concentrations due to the physiological postpartum thyrotropin surge, leading to false-positive results. The opposite is true for the screening for MCAD, VLCAD and GA-I in samples taken later than 72 h after birth when concentrations of C8- and C14-acylcarnitine and glutaryl carnitine, respectively, have dropped following the stress of birth, which is associated with increased lipolysis [22–25]. Obviously, if the sampling time is very late (>120 h) for conditions such as CAH, GALT and many inborn errors of metabolism (IEMs), neonatal screening becomes increasingly inefficient because the affected neonate may present with clinical symptoms before the screening result is available.

The transition time (i.e., the time between sampling and analysis) pertains to the time needed to send the sample to the screening laboratory per regular mail or courier. In many countries, this takes 1–3 days, but in some cases, transition time can take up to 10 or more days. Unfortunately, for countries with longer transition times, there has been little improvement over the past decade.

Early sampling (<72 h, or preferably earlier) and a short transition time benefit timely confirmatory diagnostics and treatment.

3.1.5. Analysis

Most laboratories have introduced manual or automated immunochemical assays. Tandem mass spectrometry (MS/MS) technology also has become a routine method in many countries. Croatia plans to introduce next-generation sequencing (NGS) technology as a second-tier for some conditions, which is already done in Norway to detect CF mutations and to detect mutations underlying many disorders in the programme [26].

3.1.6. Storage of DBS Cards

After analysis, the blood spot cards are discarded or stored. There are large differences in policies concerning the length of storage, varying from a few months in Germany and Ukraine up to an indefinite number of years. Many countries (43%) store samples for at least 5 years, while a minority of countries store samples for 1–2 years or less.

There is an ongoing discussion regarding whether long-term storage of the dried blood cards is useful and, if so, for how long and under what storage conditions [27]. Arguments in favour include the possibility to retrospectively check the screening result when a child unexpectedly develops a condition and the possibility to determine the prevalence and feasibility of potential additions to the panel. Arguments against long-term storage concern the traceability to personal data and the difficulty in managing long-term storage in conditioned holdings. Therefore, not only safety aspects, but also pragmatic and privacy-related aspects, come into play. In 2018, the General Data Protection Regulation (GDPR) became effective within European Union member states, requiring programmes to obtain permission from parents to store the card of their child [28]. The data shown in Table 1 indicate that only 8 of 27 EU countries require such consent even though it is now mandatory.

3.1.7. Reporting of Screening Results

Several countries make all screening results available to parents either online (e.g., through a digital patient/parent portal) or by mail. Other countries only report screening results to the health care providers and the parents only are informed if an action is required, such as a referral or a request for a second sample.

3.2. Panel of Screened Conditions

In Tables 2 and 3 the panels of conditions for neonatal screening in the European countries are presented. Whereas “x” denotes that this condition is screened for in a considerable proportion of the population, “p” denotes that the condition is screened for either in a pilot project or as part of a regional screening panel.

Historically, PKU screening was introduced first, followed by CH screening. Around 2005–2010, CAH and CF were introduced in several countries. Around the same time, MS/MS was introduced, enabling the screening of tens of additional conditions, mainly inborn errors of metabolism. We use roughly this order to discuss the current state of screening panels in the European countries.

-All countries except Montenegro screen for PKU. Finland and Malta introduced PKU screening after the gradual transition from cord blood to DBS screening. Cord blood is still used for CH screening.

-All countries except Moldova screen for primary CH. The Netherlands has also been screening for central hypothyroidism since the 1990s via the primary measurement of total thyroxine, supplemented by thyrotropin and thyroxine-binding globulin for samples, with 20% and 5% lowest total thyroxine levels, respectively [29,30]. Malta performs the simultaneous measurement of thyroxine and thyrotropin in all samples, also enabling screening for central hypothyroidism.

-Currently, screening for CF and CAH is performed in roughly 50% of the countries, almost twice as many as compared to 2010.

-The introduction of MS/MS technology in many laboratories across Europe led to a considerable increase of screening for amino acidemias (e.g., MSUD, Tyr type 1, CIT type 1), organic acidemias (e.g., GA type 1, IVA, PA, MMA) and fatty acid oxidation disorders (e.g., MCAD, LCHAD, VLCAD).

-For other conditions detectable by MS/MS, the current state is less clear. The choice to screen often depends on the medical and technical knowledge and/or the personal interest of scientists, clinicians and public health colleagues involved in the decision-making process, together with the availability of funding. This can also be influenced by patient groups who may voice support for screening. Conversely, the recognition

that the identification of mild or ambiguous phenotypes and the relatively low positive predictive value achievable for some conditions can cause stress for families and may discourage inclusion by policymakers in some countries. A few examples of conditions quite rarely screened for are MATI/III in Russia and SCAD in Hungary, Iceland, Italy and North Macedonia.

-GALK screening recently started in The Netherlands in 2020. Biotinidase deficiency screening will start in Spain in 2021. GAL screening will start in Denmark in 2021.

-SCID and xALD screening have gained growing attention in the past decade. Seven countries now screen for SCID routinely, whereas six other countries are running pilot projects or regional programmes. The Netherlands started national SCID screening in January 2021 and Ireland (using ADA) will likely start at the end of 2021. As for xALD screening, Iceland, The Netherlands and Slovenia have started pilot projects.

-Another recently started discussion concerns the inclusion of SMA in the screening panel [31,32]. Belgium and Slovakia have embarked on pilot screening projects. Germany will start nationwide SMA screening in 2021, and Spain will start a pilot screening in two regions. The Netherlands plans to implement SMA screening within 2 years.

-In Europe, the evidence for the inclusion of lysosomal storage disorders in the screening panel is regarded quite widely as insufficient. Some regions in Italy have started pilot screening projects for a panel of four lysosomal storage disorders (LSDs) [33]. The Netherlands will implement MPS-1 screening in 2021. Notably, the situation in the US is markedly different, as screening for various LSD is routinely performed in many US states.

In general, as evident by the previous data, the panel of screened disorders varies between different countries. A brief look is sufficient to reveal that budget and financial factors are not the primary causes of this heterogeneity, although they do play a role. Countries with similar economic status may present different screening panels, and these differences can sometimes be so extensive that it cannot be justified by endemic condition frequency. This is clearly not a straightforward matter, and these differences may underline existing local approaches to NBS by the corresponding expert panel in each country that decides these issues. In many cases, these differences reflect the culture of certain countries regarding being more or less 'willing' to embrace technological advancements, or they may reflect the quality of communication between the NBS performing agency and the governing agent. So, such an issue is rather difficult to analyse per se, but pointing out certain key points might help in their resolution.

3.3. Short-Term Programme Developments

In the 2020 survey, country representatives were also requested to list expected developments in their NBS programme, varying from analytical improvements and additions to the screening panel to more fundamental changes.

Conditions that may be added, for example, include CAH in Hungary and Italy, CF in Sweden, GAL in Estonia, SCID in Italy and SCD in Portugal. Cyprus, Greece and Lithuania hope to introduce MS/MS screening and hence will expand their panels considerably.

Of note is that a regional Belgium laboratory screens for haemoglobinopathies using MS/MS technology and that the UK is considering introducing this methodology. We considered the use of next-generation sequencing technology, reduced costs and greater access to MS/MS and the use of big data technology (e.g., the application of R4S/CLIR to evaluate screening results) as important changes [34–37]. Finland, Iceland, Norway and Sweden use CLIR for evaluation of individual screening results [26,38]. The Czech Republic uses the CLIR website to evaluate cut-off levels. Estonia is considering automating the exchange of data with the CLIR database, and the Netherlands and Denmark are investigating how to implement the use of CLIR in order to improve the positive predictive value of the programme.

The introduction of assays that determine cystic fibrosis transmembrane conductance regulator (CFTR) mutations in blood spot samples, e.g., by line blot assays, may have been the earliest introduction of molecular technology in the screening laboratory. Assays for

SMA and SCID in Europe are mostly assays specially adapted for screening laboratories that only need the most modest laboratory adaptations and educated personnel to perform these assays within the screening laboratory. Introducing next-generation sequencing (NGS) is yet another step forward. In the 2020 survey, only a few laboratories reported any activity in this field, with the exception of Norway and the UK. Norway is an early adaptor to this methodology and already published an analysis of NGS for CF screening in 2016 [39]. Norway has also started to use this technology as second-tier tests for IEMs and SCID [26]. The UK has conducted a limited trial of the use of NGS as part of the screening algorithm for CF and the results are being evaluated.

3.4. Future Perspectives

Looking toward the future in Europe, we identified four areas with expected significant future developments, i.e., methodological developments, developments in logistics, continuous process and effect evaluation and closer collaboration concerning the organisation of NBS in European countries.

3.4.1. Methodological Developments

Except for an obvious development in many laboratories using more biochemical second-tier testing, we identified three areas of technological expansion. One is the use of high-resolution mass spectrometry to build profiles of metabolites or compounds instead of detecting single compounds. Whereas there is some published proof of principle for this technique, there are no reports of European countries currently exploring this technology.

The second methodology is using combined demographic and analytical data to build a risk estimation for a given condition instead of predicting the concentration of a single metabolite and/or metabolite ratios with corresponding cut-off values [37] (see also the special issue in this journal). In theory, this would yield far superior performance of neonatal screening, but initiatives to use CLIR need to still take off in Europe. Two reasons for the delay are the lack of covariate data such as birth weight, gestational age, sex and sampling time in hours on the screening cards, and the feasibility of laboratory information systems to exchange data with CLIR-like big data facilities preserving patient data safety.

Then, there is NGS technology, which is very versatile and could develop into a technology that would potentially be able to screen for, e.g., SMA, CF, SCID and other monogenic diseases in one sample [26]. The expansion of NGS technology in Europe needs to be awaited. Molecular technology will claim its place in the screening laboratory. Simplified molecular technology, adapted to work in the high-throughput environment of the screening laboratory, has already been implemented in the European laboratories screening for CF, SCID and SMA. A careful analysis of the way in which this is used will be important to avoid adding to uncertainty when classifying individual NGS screening results.

3.4.2. Logistical Developments

For many decades, the sample card with demographic details, put in a paper envelope and sent to the laboratory by regular mail or a courier, has been the norm. However, some screening programmes are now modernising this process. Instead of writing the demographic data on the card, this data can also be added in a neonatal screening portal, where the screener connects the barcoded or QR-coded sample card with the demographics. Obvious advantages are that the size of the card is not limiting for the amount of information that the laboratory requests; that the sampling card will be sent to the laboratory without identifying personal data, avoiding the risk of incidental release of privacy sensitive details in case a sample is intercepted; and that screeners can avoid clerical errors when entering written data in the laboratory information management system. Such a system may also facilitate a parent portal to report the screening results to parents. This may be especially useful in those countries that report all results to parents, as well as when the screening result is negative.

3.4.3. Process and Effect Evaluation

One item that has not yet been surveyed at length is how NBS programmes establish performance indicators such as sensitivity, specificity and predictive values. We should attempt to compare and contrast conditions with respect to the extent to which the screening programmes have been effective in reducing morbidity or mortality for each of the conditions, represent value for money and have benefits that outweigh their detriments. Countries may have an extensive panel of conditions and a relatively small annual screening volume. It would then take many years to obtain sufficient information about the screening performance for each individual condition. Therefore, use of the large CLIR database and infrastructure is recommended [34]. In addition, close collaboration between the screening laboratory professionals, the metabolic paediatricians, primary care providers and, ideally, clinical epidemiologists, is essential to be able to compare the screening results and the short-term and long-term clinical outcome, preferably using a common database in which all results per infant are registered and evaluated periodically. In this way, a good overview of false-positives and false-negatives can be obtained, which may lead to further methodological improvements.

Another item for thought is the question of whether NBS programmes have set performance goals, such as increasing coverage (if applicable), increasing positive predictive values, laboratory time to result, minimising clerical errors and the follow-up of patients picked up by the programmes. European collaboration regarding the use of international databases and tools could further support programme improvement within Europe.

We realise that there are a lot of data to be scrutinised. Many screening tests are performed quite differently, e.g., CF screening can be performed in a one-one to four-tier procedure depending on the country where the screening is performed. For CAH screening, various algorithms exist in case a result is intermediate. A second sampling is often performed, and some laboratories have second-tier tests in place. Whereas it is clear that this level of detail is not within the scope of this study, an even more detailed state of affairs may be explored in future surveys. In particular, the performance indicators of programmes should be evaluated, as this would identify best practices. For this, immaculately organized follow-up is needed, although at least robust reporting of false-positive results could be a very good quality indicator. Given that these are all rare diseases, and that most countries will find none to a few in a decade, it is clear that European collaboration concerning the collection of data is very important.

3.4.4. Closer Collaboration Concerning the Organisation of NBS across Europe

In spite of the consensus concerning the value of NBS, there are large differences among countries on how NBS is embedded in the health care systems, how the intake of infants is done, at what time after birth and by whom, how the parents are informed and sometimes asked for written consent, how parents and caretakers are informed about the screening results and the subsequent action for referral and treatment.

Each country is governed independently and makes its own decisions concerning conditions that should be included in NBS. Unlike the USA, where public opinions can influence NBS policies to a great extent, there is little public knowledge concerning the health care organisation in neighbouring countries. As a consequence, advocacy efforts concerning health policies across borders are limited.

In Europe, health care is usually funded through a national health service or a statutory health insurance (social security). In almost every jurisdiction, public health care systems have defined mechanisms to assess and appraise payment for NBS, and most allow for diverse stakeholder participation when considering technology effectiveness, disease severity, the health economy and treatment availability. This often results in complex governmental (financial) decisions when expansion to include new conditions is considered.

Tables 2 and 3 show the large variations among countries. Since the previous study concerning the situation in 2010 [18], there have been major changes in the screening panels, largely due to the increased availability of MS/MS technology making it possible to obtain

the results for 10–15 conditions in using single DBS sample. Yet, the appreciation of the value of screening for certain conditions differs and seems to depend, to a certain extent, on the available knowledge and interest of leading (para)medical opinion leaders.

The assessment of long-term outcomes for patients identified by screening can best be achieved by international collaboration. The disorders are rare, and the use of international disease registries founded upon agreed case definitions continues to be a pressing area where progress is required. Notable advances such as the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) and the European Registry and Network for Homocystinurias and Methylation Defects (E-HOD) offer encouragement. In addition, prioritization criteria for genetic testing services regarding medical benefits, health needs and cost have been proposed [40].

There are currently no policy recommendations for NBS, nor is there direct oversight at the European level or within the EU [16]. Over time, the EU, consisting of 27 countries as of 2021, has established several treaties on topics to be governed or overseen by the European Commission (EU's Executive Body). However, health care has not been included because the member states consider it to be their own responsibility (principle of subsidiarity). To add complexity, in some EU countries, e.g., Belgium, Germany, Italy and Spain, as well as in the UK, policymaking is decentralized to regions or provinces that function more or less autonomously.

There may be some hope from the creation by the EU of the European Reference Networks for the diagnosis and treatment of rare diseases, including inherited metabolic disorders, immune deficiencies and some rare endocrine disorders. The screening community must emphasise that the patients involved are, for a large part, identified by NBS, and that appropriate screening programmes should form an integral part of these important networks as they develop [16].

4. Conclusions

Between 2010 and 2020, most NBS programmes in geographical Europe matured considerably, both in terms of methodology (modernised) and with regard to the panel of conditions screened (expanded). It must be noted that the results presented here are subject to new changes within a short time window. The ISNS is in the process of establishing a database which is available for public consultation [41].

This paper reports a cross-sectional study of European screening programmes. It should inspire the programmes to produce per-country disorder-based overviews to compare screening performance, diagnostic confirmation and therapeutical follow-up.

Personal contacts between and among programme leaders have been stimulated by the ISNS during conferences and workshops. On a European level, the ISNS recently established close links with the International Patient Organization for Primary Immunodeficiencies (IPOPI), the European Reference Network for Hereditary Metabolic Diseases and Rare Endocrine disorders (metabERN/EndoERN) and the European Organization for Rare Disease (EURORDIS). In addition, the ISNS, IPOPI and the European Society for Immunodeficiencies (ESID) are in the process of establishing a stakeholder platform for neonatal screening as part of the EU Health Policy Platform, called Screen4Rare.

Together, these developments indicate that more collaboration in Europe through European organisations is gaining momentum. Whether this will ultimately lead to, e.g., a European draft priority list for neonatal DBS screening for various conditions [15] to assist policymakers faced by the wide variation in the current practice of neonatal DBS screening within Europe, taking into account published international guidelines such as those by the ISNS [42], or whether Europe will choose another path toward more collaboration, remains to be seen.

We can only accomplish the timely detection of newborns potentially suffering from one of the many rare diseases and take appropriate action, and prepare for the implementation of new developments for all European citizens, by working together.

Supplementary Materials: The following are available online at <https://www.mdpi.com/2409-515X/7/1/15/s1>, Supplementary File S1: ISNS Survey NBS in Europe 2010–2018; Supplementary File S2: ISNS Survey NBS in Europe 2020.

Author Contributions: J.G.L., D.P., R.H.Z. and P.J.C.I.S. contributed to the design and writing. All authors contributed data from their respective countries. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors acknowledge V. Mitkin, Moscow, Russia, for establishing contacts with colleagues in the former USSR republics and the collection of the data from their countries: R.Guseinov, Azarbaijan; N.Gusina, Belarus; B.Nurbek, Kyrgyzstan; S.Amansahedova, Turkmenistan. Additional data were obtained from M.B.Ivanova, Bulgaria; K.Reinson, Estonia, supported by Estonian Research Council grant PRG471; U.Nennstiel, Germany; A van Gorp and R.Maase, the Netherlands; V.Anastasovska, North Macedonia.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

3HMG	3-Hydroxy-3-methylglutaric aciduria
3MCC	3-Methylcrotonyl-CoA carboxylase deficiency/3-Methylglutacon aciduria/2-methyl-3-OH-butyric aciduria
AAD	Disorders of amino acid metabolism
x-ALD	x-Adrenoleukodystrophy
ARG	Argininemia
ASA	Argininosuccinic aciduria
BIO	Biotinidase deficiency
BKT	Beta-ketothiolase deficiency
CACT	Carnitine acylcarnitine translocase deficiency
CAH	Congenital adrenal hyperplasia
CF	Cystic fibrosis
CFTR	cystic fibrosis transmembrane conductance regulator
CH	(primary) Congenital hypothyroidism
CIT1	Citrullinaemia type I
CIT2	Citrullinaemia type II
CPT1	Carnitine palmitoyltransferase deficiency type I
CPT2	Carnitine palmitoyltransferase type II-/Carnitine acylcarnitine transporter deficiency
CUD	Carnitine uptake defect
E-HOD	European Registry and Network for Homocystinurias and Methylation Defects
E-IMD	European Registry and Network for Intoxication type Metabolic Diseases
ESID	European Society for Immunodeficiencies
EUNENBS	European Network of Experts on Newborn Screening
EURORDIS	European Organisation for Rare Diseases
FAOD	Disorders of fatty acid metabolism
G6PD	Glucose-6-phosphate dehydrogenase deficiency
GA1	Glutaric acidaemia type I
GA2	Glutaric acidaemia type II or multiple acyl coA dehydrogenase deficiency
GAL	Classical galactosaemia
GALK	Galactose kinase deficiency
HCY	Homocystinuria (CBS deficiency)
HCS	Holocarboxylase synthetase deficiency
Hemo	Haemoglobinopathies
HPLC	High performance liquid chromatography
IPOPI	International Patient Organization for Primary Immunodeficiencies
IVA	Isovaleric acidaemia (IVA)/2-Methylbutyrylglycinuria
LCHAD	Long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency/ Trifunctional protein deficiency

LSD	Lysosomal storage disorder
M	Miscellaneous disorders
MAT I/III	Methionine adenosyl transferase I/III deficiency
MCAD	Medium-chain acyl-CoA dehydrogenase deficiency
MCD	Multiple carboxylase deficiency
MMA	Methylmalonic acidaemia
MSUD	Maple Syrup Urine Disease
NBS	Neonatal (Newborn) Screening
NGS	Next generation sequencing
OA	Disorders of organic acid metabolism
PA	Propionic acidaemia
PKU/HPA	Phenylketonuria/Hyperphenylalaninaemia
RMD	Remethylation disorders (methylenetetrahydrofolate reductase, methylcobalamine deficiencies)
SCD	Sickle cell disease/thalassemia
SCID	Severe Combined Immunodeficiencies
SCAD	Short-chain acyl-CoA dehydrogenase deficiency
SMA	Spinal muscular atrophy
TFP	Trifunctional protein deficiency
TYR1	Tyrosinaemia type 1
TYR2	Tyrosinaemia type 2
UDP	UDP-galactose-4-epimerase deficiency
UK	United Kingdom
VLCAD	Very long-chain acyl-CoA dehydrogenase deficiency

References

1. Woolf, L.I.; Adams, J. The Early History of PKU. *Int. J. Neonatal Screen.* **2020**, *6*, 59. [[CrossRef](#)] [[PubMed](#)]
2. Fölling, I.A. Über Ausscheidung von phenylbrenztraubensäure in den harn als stoffwechselanomalie in verbindung mit imbezilität. *Hoppe Seyler's Z. Physiol. Chem.* **1934**, *227*, 169–181. (In German) [[CrossRef](#)]
3. Centerwall, W.R. Phenylketonuria. *J. Am. Med. Assoc.* **1957**, *165*, 392. [[CrossRef](#)]
4. Laxova, R. Lionel Sharples Penrose, 1898–1972: A personal memoir in celebration of the centenary of his birth. *Genetics* **1998**, *150*, 1333–1340. [[PubMed](#)]
5. Guthrie, R.; Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. *Pediatrics* **1963**, *32*, 338–343. [[PubMed](#)]
6. Dussault, J.H.; Laberge, C. Thyroxine (T4) determination by radioimmunological method in dried blood eluate: New diagnostic method of neonatal hypothyroidism? *Union Med. Can.* **1973**, *102*, 2062–2064.
7. Millington, D.S.; Kodo, N.; Norwood, D.L.; Roe, C.R. Tandem mass spectrometry: A new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. *J. Inherit. Metab. Dis.* **1990**, *13*, 321–324. [[CrossRef](#)] [[PubMed](#)]
8. Rashed, M.S.; Ozand, P.T.; Harrison, M.E.; Watkins, P.J.F.; Evans, S.; Baillie, P.T.A. Electrospray tandem mass spectrometry in the diagnosis of organic acidemias. *Rapid Commun. Mass Spectrom.* **1994**, *8*, 129–133. [[CrossRef](#)]
9. Schulze, A.; Lindner, M.; Kohlmüller, D.; Olgemöller, K.; Mayatepek, E.; Hoffmann, G.F. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: Results, outcome, and implications. *Pediatrics* **2003**, *111*, 1399–1406. [[CrossRef](#)]
10. Wilson, J.M.; Jungner, Y.G. Principles and practice of mass screening for disease. *Bull. WHO* **1968**, *65*, 281–393.
11. International Society for Neonatal Screening—Region Europe. Available online: <https://www.isns-neoscreening.org/isns-regions/region-europe/> (accessed on 18 November 2020).
12. Wikipedia. List of European Countries by Population. Available online: https://en.wikipedia.org/wiki/List_of_European_countries_by_population (accessed on 27 September 2020).
13. World Bank Data. Birth Rate. Available online: <https://data.worldbank.org/indicator/sp.dyn.cbtr.in> (accessed on 27 September 2020).
14. Burgard, P.; Cornel, M.C.; Di Filippo, F.; Heage, G.; Hoffmann, G.F.; Lindner, M.; Loeber, J.G.; Rigter, T.; Rupp, K.; Taruscio, D.; et al. *Short Executive Summary of the Report on the Practices of Newborn Screening for Rare Disorders in Member States of the European Union, Candidate and Potential Candidate, and EFTA Countries*; International Society for Neonatal Screening: Bilthoven, The Netherlands, 2011; Available online: <http://www.isns-neoscreening.org/wp-content/uploads/2016/06/Summary20111018.pdf> (accessed on 18 November 2020).
15. Cornel, M.C.; Rigter, T.; Weinreich, S.S.; Burgard, P.; Hoffmann, G.F.; Lindner, M.; Loeber, J.G.; Rupp, K.; Taruscio, D.; Vittozzi, L. Newborn screening in Europe; expert opinion document. *Eur. J. Hum. Genet.* **2014**, *22*, 12–17. [[CrossRef](#)]

16. Loeber, J.G. European union should actively stimulate and harmonise neonatal screening initiatives. *Int. J. Neonatal Screen.* **2018**, *4*, 32. [[CrossRef](#)] [[PubMed](#)]
17. Loeber, J.G. Neonatal screening in Europe; situation in 2004. *J. Inher. Metab. Dis.* **2007**, *30*, 430–438. [[CrossRef](#)]
18. Loeber, J.G.; Burgard, P.; Cornel, M.C.; Rigter, T.; Weinreich, S.S.; Rupp, K.; Hoffmann, G.F.; Vittozzi, L. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1—From blood spot to screening result. *J. Inher. Metab. Dis.* **2012**, *35*, 603–611. [[CrossRef](#)] [[PubMed](#)]
19. Burgard, P.; Rupp, K.; Lindner, M.; Haege, G.; Rigter, T.; Weinreich, S.S.; Loeber, J.G.; Taruscio, D.; Vittozzi, L.; Cornel, M.C.; et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2—From screening laboratory results to treatment, follow-up and quality assurance. *J. Inher. Metab. Dis.* **2012**, *35*, 613–625. [[CrossRef](#)] [[PubMed](#)]
20. Therrell, B.L.; Padilla, C.D.; Loeber, J.G.; Kneisser, I.; Saadallah, A.; Borrajo, G.J.; Adams, J. Current status of newborn screening worldwide: 2015. *Semin. Perinatol.* **2015**, *39*, 171–187. [[CrossRef](#)] [[PubMed](#)]
21. Groselj, U.; Tansek, M.Z.; Smon, A.; Angelkova, N.; Anton, D.; Baric, I.; Djordjevic, M.; Grimci, L.; Ivanova, M.; Kadam, A.; et al. Newborn screening in southeastern Europe. *Mol. Genet. Metab.* **2014**, *113*, 42–45. [[CrossRef](#)]
22. Roscher, A. Unpublished work. 2021.
23. Estrella, J.; Wilcken, B.; Carpenter, K.; Bhattacharya, K.; Tchan, M.; Wiley, V. Expanded newborn screening in New South Wales: Missed cases. *J. Inher. Metab. Dis.* **2014**, *37*, 881–887. [[CrossRef](#)]
24. Boneh, A.; Andresen, B.S.; Gregersen, N.; Ibrahim, M.; Tzanakos, N.; Peters, H.; Yaplitto-Lee, J.; Pitt, J. VLCAD deficiency: Pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. *Mol. Genet. Metab.* **2006**, *88*, 166–170. [[CrossRef](#)]
25. Schymik, I.; Liebig, M.; Mueller, M.; Wendel, U.; Mayatepek, E.; Strauss, A.W.; Wanders, R.J.A.; Spiekeroetter, U. Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. *J. Pediatrics* **2006**, *149*, 128–130. [[CrossRef](#)]
26. Tangeraas, T.; Sæves, I.; Klingenberg, C.; Jørgensen, J.; Kristensen, E.; Gunnarsdottir, G.; Hansen, E.; Strand, J.; Lundman, E.; Ferdinandusse, S.; et al. Performance of expanded newborn screening in Norway supported by post-analytical bioinformatics tools and rapid second-tier dna analyses. *Int. J. Neonatal Screen.* **2020**, *6*, 51. [[CrossRef](#)]
27. Van Rijt, W.J.; Schielen, P.C.; Özer, Y.; Bijsterveld, K.; Van der Sluijs, F.H.; Derks, T.G.; Heiner-Fokkema, M.R. Instability of acylcarnitines in stored dried blood spots: The impact on retrospective analysis of biomarkers for inborn errors of metabolism. *Int. J. Neonatal Screen.* **2020**, *6*, 83–95. [[CrossRef](#)]
28. General Data Protection Regulation (GDPR) 2016. Available online: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32016R0679> (accessed on 18 November 2020).
29. Lanting, C.I.; Van Tijn, D.A.; Loeber, J.G.; Vulsma, T.; de Vijlder, J.J.; Verkerk, P.H. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. *Pediatrics* **2005**, *116*, 168–173. [[CrossRef](#)] [[PubMed](#)]
30. Stroek, K.; Heijboer, A.C.; Bouva, M.J.; Van der Ploeg, C.P.B.; Heijnen, M.-L.A.; Weijman, G.; Bosch, A.M.; De Jonge, R.; Schielen, P.C.J.I.; Van Trotsenburg, A.S.P.; et al. Critical evaluation of the newborn screening for congenital hypothyroidism in the Netherlands. *Eur. J. Endocrinol.* **2020**, *183*, 265–273. [[CrossRef](#)] [[PubMed](#)]
31. Boemer, F.; Caberg, J.-H.; Dideberg, V.; Dardenne, D.; Bours, V.; Hiligsmann, M.; Dangouloff, T.; Servais, L. Newborn screening for SMA in Southern Belgium. *Neuromuscul. Disord.* **2019**, *29*, 343–349. [[CrossRef](#)]
32. Vill, K.; Köbel, H.; Schwartz, O.; Blaschek, A.; Olgemöller, B.; Harms, E.; Burggraf, S.; Röschinger, W.; Dumer, J.; Gläser, D.; et al. One year of newborn screening for SMA. Results of a German pilot project. *J. Neuromuscul. Dis.* **2019**, *6*, 503–515. [[CrossRef](#)] [[PubMed](#)]
33. Burlina, A.B.; Polo, G.; Salviati, L.; Duro, G.; Zizzo, C.; Dardis, A.; Bembi, B.; Cazzorla, C.; Rubert, L.; Zordan, R.; et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. *J. Inher. Metab. Dis.* **2018**, *41*, 209–219. [[CrossRef](#)] [[PubMed](#)]
34. CLIR—Collaborative Laboratory Integrated Reports. Available online: <https://clir.mayo.edu/> (accessed on 15 December 2020).
35. McHugh, D.; Cameron, C.A.; Abdenur, J.E.; Abdulrahman, M.; Adair, O.; Al Nuaimi, S.A.; Ahlman, H.; Allen, J.J.; Antonozzi, I.; Archer, S.; et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. *Genet. Med.* **2011**, *13*, 230–254. [[CrossRef](#)]
36. Marquardt, G.; Currier, R.; McHugh, D.M.; Gavrilov, D.; Magera, M.J.; Matern, D.; Oglesbee, D.; Raymond, K.; Rinaldo, P.; Smith, E.H.; et al. Enhanced interpretation of newborn screening results without analyte cutoff values. *Genet. Med.* **2012**, *14*, 648–655. [[CrossRef](#)]
37. Baerg, M.M.M.; Stoway, S.D.; Hart, J.; Mott, L.; Peck, D.S.; Nett, S.L.; Eckerman, J.S.; Lacey, J.M.; Turgeon, C.T.; Gavrilov, D.; et al. Precision newborn screening for lysosomal disorders. *Genet. Med.* **2018**, *20*, 847–854. [[CrossRef](#)]
38. Sörensen, L.; Von Döbeln, U.; Åhlman, H.; Ohlsson, A.; Engvall, M.; Naess, K.; Backman-Johansson, C.; Nordqvist, Y.; Wedell, A.; Zetterström, R.H. Expanded screening of one million Swedish babies with R4S and CLIR for post-analytical evaluation of data. *Int. J. Neonatal Screen.* **2020**, *6*, 42. [[CrossRef](#)] [[PubMed](#)]
39. Lundman, E.; Gaup, H.J.; Bakkeheim, E.; Olafsdottir, E.J.; Rootwelt, T.; Storrøsten, O.T.; Pettersen, R.D. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years. *J. Cyst. Fibros.* **2016**, *15*, 318–324. [[CrossRef](#)] [[PubMed](#)]

-
40. Severin, F.; Borry, P.; Cornel, M.C.; Daniels, N.; Fellmann, F.; Hodgson, S.V.; Howard, H.C.; John, J.; Kääriäinen, H.; Kayserili, H.; et al. Points to consider for prioritizing clinical genetic testing services: A European consensus process oriented at accountability for reasonableness. *Eur. J. Hum. Genet.* **2015**, *23*, 729–735. [[CrossRef](#)] [[PubMed](#)]
 41. International Society for Neonatal Screening. Databank Disorders. Available online: <https://membership.isns-neoscreening.org/disorders/> (accessed on 15 December 2020).
 42. International Society for Neonatal Screening. Guidelines. Available online: <https://www.isns-neoscreening.org/isns-general-guidelines-for-neonatal-screening/> (accessed on 15 December 2020).